Scarica l'app Stockscreener
10.01
0.00%
0.00
Precedente Chiudi:
$10.01
Aprire:
$10.01
Volume 24 ore:
381.88K
Relative Volume:
18.57
Capitalizzazione di mercato:
$219.29M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+32.81%
6M Prestazione:
+20.48%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.01
$10.02
Intervallo di 1 settimana:
$10.00
$10.02
Portata 52W:
$10.00
$10.02
Translational Development Acquisition Corp Stock (TDAC) Company Profile
Nome
Translational Development Acquisition Corp
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TDAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.01 | 219.29M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.31 | 2.40B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.06 | 691.25M | 0 | 16.92M | -1.35M | 0.29 |
|
GCL
Gcl Global Holdings Ltd
|
3.77 | 475.87M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.55 | 454.97M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.17 | 447.22M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-21 | Iniziato | Northland Capital | Outperform |
Translational Development Acquisition Corp Borsa (TDAC) Ultime notizie
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
FirstEnergy issues earnings report - 69News WFMZ-TV
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Research and Development grant cheat sheet - University of Sydney
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
BioSpace Movers & Shakers, March 19 - BioSpace
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Quotient Clinical’s second U.S. acquisition in a row: Charles River’s QS Pharma - Fierce Biotech
People - Nature.com
Translational Development Acquisition Corp Azioni (TDAC) Dati Finanziari
Non sono disponibili dati finanziari per Translational Development Acquisition Corp (TDAC). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):